Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KRYS - Krystal Biotech Inc


IEX Last Trade
194.82
-0.400   -0.205%

Share volume: 202,808
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$195.22
-0.40
-0.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
15%
Profitability 15%
Dept financing 2%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-3.20%
1 Month
-3.83%
3 Months
20.74%
6 Months
19.65%
1 Year
53.01%
2 Year
181.36%
Key data
Stock price
$194.82
P/E Ratio 
0.00
DAY RANGE
$191.33 - N/A
EPS 
$0.00
52 WEEK RANGE
$93.95 - $219.34
52 WEEK CHANGE
$0.55
MARKET CAP 
5.606 B
YIELD 
N/A
SHARES OUTSTANDING 
28.730 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$178,416
AVERAGE 30 VOLUME 
$244,111
Company detail
CEO: Krish S. Krishnan
Region: US
Website: https://www.krystalbio.com/
Employees: 188
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)

Recent news